Biotix

FierceBiotech | June 22, 2018

A phase 2/3 trial of Nanobiotix’s NBTXR3 in soft tissue sarcoma has met (PDF) its primary endpoint. The top-line success against the pathological complete response rate endpoint sent Nanobiotix’s stock up by more than 50%.NBTXR3 consists of crystalline nanoparticles designed to enhance the efficacy of radiation therapy. By administering intratumoral injections of the nanoparticles prior to external beam radiation therapy, Nanobiotix thinks it can dial up the antitumor effect, thereby...

Medical, Industry Outlook

Globenewswire | July 13, 2023

NANOBIOTIX a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. NBTXR3 is currently being evaluated in several studies across solid tumor in...

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...